NEW YORK: Merck Serono announced its collaboration with US biopharmaceutical company Ambrx, Inc. to develop and commercialize Ambrx's long-acting growth hormone products.
The collaboration will focus initially on the development of ARX201, the most advanced product candidate, currently in Phase I/II clinical trials. ARX201 has improved pharmacological properties, which should allow less frequent administration than the daily dosing regimen of currently available growth hormones.
Under the terms of the agreement, Merck Serono will receive worldwide commercialization rights for ARX201. Merck Serono will make an initial payment to Ambrx, and Ambrx is eligible to receive undisclosed clinical, regulatory and commercial milestone payments based on the successful development and commercialization of products, as well as undisclosed royalties on net sales of such products.
In addition, Ambrx retains an option to co-promote products in the US market. If the option is exercised, Ambrx and Merck Serono will share US commercialization expenses as well as profits. In the event Ambrx declines to exercise its option, it will receive undisclosed royalties on net sales of products worldwide.
"Merck Serono has a long-term commitment to children and adults with disorders requiring growth hormone treatment," said François Feig, Head of Global Therapeutic Area Endocrinology and Cardio-Metabolic Care, Merck Serono.
Print
Tell friend
Top
